Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ATTR
Biotech
Intellia stock sinks on gene therapy patient's raised enzymes
Intellia’s stock may have taken a hit in the wake of details of a grade 4 adverse event in a phase 3 trial, but analysts are keeping faith.
James Waldron
May 29, 2025 9:15am
BridgeBio touts case for acoramidis with post hoc study analysis
Sep 30, 2024 9:37am
Intellia doesn't need to re-dose NTLA-2001. But it can be done
Jun 25, 2024 3:31pm
Bayer pays $310M for Europe rights to BridgeBio's Vyndaqel rival
Mar 4, 2024 8:22am
AstraZeneca's heart disease trial hits, teeing up Pfizer clash
Feb 2, 2024 6:43am
BridgeBio taps investors for $1.25B to fund showdown with Pfizer
Jan 18, 2024 8:04am
